# China NMPA Drug Inspection - Chengdu Jinhua Pharmaceutical Co., Ltd. - Chinese medicinal herbs, including Paris polyphylla.

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/chengdu-jinhua-pharmaceutical-co-ltd/61a09dd6-5938-48d3-a5df-f16b11641e71/
Source feed: China

> China NMPA drug inspection for Chengdu Jinhua Pharmaceutical Co., Ltd. published October 22, 2019. Drug: Chinese medicinal herbs, including Paris polyphylla.. The Sichuan Provincial Drug Administration issued an announcement on October 22, 2019, detailing findings from its 2019 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Provincial Drug Administration's Sichuan Provincial Drug Quality Bulletin (Sixth Issue, 2019)
- Company Name: Chengdu Jinhua Pharmaceutical Co., Ltd.
- Publication Date: 2019-10-22
- Drug Name: Chinese medicinal herbs, including Paris polyphylla.
- Inspection Finding: [Characteristics]
- Action Taken: The relevant drug regulatory authorities have investigated and dealt with the matter in accordance with laws and regulations, and have required the relevant companies to suspend sales and use, recall products, conduct investigations into the reasons for non-compliance, and carry out thorough rectification.
- Summary: The Sichuan Provincial Drug Administration issued an announcement on October 22, 2019, detailing findings from its 2019 drug sampling inspection program. This initiative, conducted by drug supervision departments across various cities and prefectures, aimed to ensure compliance within drug production, distribution, and use units throughout 2019. The inspections identified 23 batches of non-compliant drugs from various manufacturers, including Jilin Wantong Pharmaceutical Co., Ltd., Changchun Yinnuoke Drug Industry Co., Ltd., and Sichuan Yunbotang Pharmacy Pharmaceutical Co., Ltd., among others. Violations primarily involved deviations from national drug standards and the Chinese Pharmacopoeia. Common issues included non-conformance in drug appearance, excessive moisture content, presence of mold and yeast, discrepancies in packing quantity, improper content determination of active ingredients, and issues with acid-insoluble ash or other properties. In response to these findings, the regulatory authorities have mandated immediate actions. Affected enterprises are required to suspend sales and use of the non-compliant products, initiate product recalls, investigate the root causes of the non-conformities, and implement comprehensive corrective measures to ensure full compliance with regulatory requirements. This enforcement action underscores the administration's commitment to upholding drug quality and patient safety within the region.

Company: https://www.globalkeysolutions.net/companies/chengdu-jinhua-pharmaceutical-co-ltd/9946188f-fdd2-423d-b567-e672fded628d/